231 results on '"de la Puente, Pilar"'
Search Results
2. Reprogramming of normal fibroblasts into ovarian cancer-associated fibroblasts via non-vesicular paracrine signaling induces an activated fibroblast phenotype
3. A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma
4. Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma
5. Normal Uterine Fibroblast Are Reprogramed into Ovarian Cancer-Associated Fibroblasts by Ovarian Tumor-derived Conditioned Media
6. Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma
7. The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma
8. Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma
9. Mimicking tumor hypoxia and tumor-immune interactions employing three-dimensional in vitro models
10. Thermal Sensitive Liposomes Improve Delivery of Boronated Agents for Boron Neutron Capture Therapy
11. Data from Hypoxia Promotes Dissemination and Colonization in New Bone Marrow Niches in Waldenström Macroglobulinemia
12. Supplementary Figure 2 from Hypoxia Promotes Dissemination and Colonization in New Bone Marrow Niches in Waldenström Macroglobulinemia
13. Supplementary Figure 1 from Hypoxia Promotes Dissemination and Colonization in New Bone Marrow Niches in Waldenström Macroglobulinemia
14. Supplementary Figure Legend from Hypoxia Promotes Dissemination and Colonization in New Bone Marrow Niches in Waldenström Macroglobulinemia
15. The WNK1–ERK5 route plays a pathophysiological role in ovarian cancer and limits therapeutic efficacy of trametinib
16. 3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma
17. Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia
18. BASIN: A Semi-automatic Workflow, with Machine Learning Segmentation, for Objective Statistical Analysis of Biomedical and Biofilm Image Datasets
19. Delivery systems for brachytherapy
20. Cell culture in autologous fibrin scaffolds for applications in tissue engineering
21. A Hypoxia-Targeted Boron Neutron Capture Therapy Agent for the Treatment of Glioma
22. Differentiation within autologous fibrin scaffolds of porcine dermal cells with the mesenchymal stem cell phenotype
23. Advancements in Tumor Targeting Strategies for Boron Neutron Capture Therapy
24. Reduction of Metastasis via Epigenetic Modulation in a Murine Model of Metastatic Triple Negative Breast Cancer (TNBC)
25. A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma
26. Leukemia Inhibitory Factor: An Important Cytokine in Pathologies and Cancer
27. 3D Tissue-Engineered Bone Marrow Culture Predicts Patient Response to Drugs in Multiple Myeloma
28. PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance
29. 3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance
30. Bioengineering the Oxygen-Deprived Tumor Microenvironment Within a Three-Dimensional Platform for Studying Tumor-Immune Interactions
31. Human Plasma-Derived 3D Cultures Model Breast Cancer Treatment Responses and Predict Clinically Effective Drug Treatment Concentrations
32. Abstract B29: Modeling the oxygen-deprived breast cancer tumor microenvironment within a three-dimensional bioengineered platform that exhibits hypoxia-driven immune evasion
33. Abstract A22: Feasibility and efficacy of a human-derived plasma 3D culture (huP3D) model to predict clinically effective drug treatment concentrations
34. Abstract A27: Endothelial progenitor cells as drug-delivery Trojan horses for treatment and imaging of cancer
35. Abstract B01: Nanoparticle multispecific T-cell engagers for the treatment of multiple myeloma
36. Analysis of Dual Class I Histone Deacetylase and Lysine Demethylase Inhibitor Domatinostat (4SC-202) on Growth and Cellular and Genomic Landscape of Atypical Teratoid/Rhabdoid
37. Bioengineering a novel 3D in-vitro model to recreate physiological oxygen levels and tumor-immune interactions
38. PYK2/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma
39. 3D-Tissue Engineered Bone Marrow (3DTEBM) Culture Retrospectively Predicts Treatment Clinical Outcomes of Multiple Myeloma Patients
40. Cuadro de mando basado en IoT para la Gestión Energética
41. Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance
42. Nanoparticle delivery systems, general approaches, and their implementation in multiple myeloma
43. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy
44. Anti-CD38 Targeted Nanoparticles for Drug Delivery in Multiple Myeloma
45. Novel Flow Cytometry-Based Biomarkers Predict Recurrence in Myeloma Patients through Detection of MRD in the Bone Marrow and CTCs in Peripheral Blood
46. 3D tissue-engineered bone marrow: what does this mean for the treatment of multiple myeloma?
47. Molecularly Targeted Therapies in Multiple Myeloma
48. Hypoxia Induces Pgp-Mediated Carfilzomib Resistance in Multiple Myeloma Cells and HIF Inhibition Significantly Enhances Sensitivity and Response to Carfilzomib In Vivo
49. Integrin-Linked Kinase a Novel Therapeutic Target for Acute and Chronic Myeloid Leukemia
50. Tris DBA Palladium Overcomes Hypoxia Mediated Drug Resistance in Multiple Myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.